Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8844)
All Articles published online
|
Publishing Process of This Article
|
Mar 21, 2017 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zheng MK, Shih DQ, Chen GC. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(11): 1932-1943 [PMID: 28373759 DOI: 10.3748/wjg.v23.i11.1932] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i11/1932.htm |
| Number | Citing Articles |
| 1 |
Sandra Maria Barbalho, Ricardo de Alvares Goulart, Rodrigo Gallhardi Gasparini. Associations between inflammatory bowel diseases and vitamin D. Critical Reviews in Food Science and Nutrition 2019; 59(8): 1347 doi: 10.1080/10408398.2017.1406333
|
| 2 |
Meng-Chen Lee, Yi-Cheng Huang. Soluble eggshell membrane protein-loaded chitosan/fucoidan nanoparticles for treatment of defective intestinal epithelial cells. International Journal of Biological Macromolecules 2019; 131: 949 doi: 10.1016/j.ijbiomac.2019.03.113
|
| 3 |
Evelien Moorkens, Arnold G. Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sović-Brkičić, Juraj Slabý, Robin Šebesta, Ott Laius, Allan Karr, Morgane Beck, Jaana E. Martikainen, Gisbert W. Selke, Susan Spillane, Laura McCullagh, Gianluca Trifirò, Patricia Vella Bonanno, Asbjørn Mack, Antra Fogele, Anita Viksna, Magdalena Władysiuk, Helder Mota-Filipe, Dmitry Meshkov, Marija Kalaba, Simona Mencej Bedrač, Jurij Fürst, Corrine Zara, Peter Skiöld, Einar Magnússon, Steven Simoens, Tomasz Bochenek. Policies for biosimilar uptake in Europe: An overview. PLOS ONE 2017; 12(12): e0190147 doi: 10.1371/journal.pone.0190147
|
| 4 |
Glen T. Schumock, JoAnn Stubbings, Michelle D. Wiest, Edward C. Li, Katie J. Suda, Linda M. Matusiak, Robert J. Hunkler, Lee C. Vermeulen. National trends in prescription drug expenditures and projections for 2018. American Journal of Health-System Pharmacy 2018; 75(14): 1023 doi: 10.2146/ajhp180138
|
| 5 |
Lissy de Ridder, Amit Assa, Jiri Bronsky, Claudio Romano, Richard K. Russell, Nadeem A. Afzal, Almuthe C. Hauer, Daniela Knafelz, Paolo Lionetti, Caterina Strisciuglio, Gábor Veres, Harland Winter, Victorien M. Wolters, Malgorzata Sladek, Arnold G. Vulto, Jorge A. Dias. Use of Biosimilars in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition 2019; 68(1): 144 doi: 10.1097/MPG.0000000000002141
|
| 6 |
Sophie Steeland, Claude Libert, Roosmarijn E. Vandenbroucke. A New Venue of TNF Targeting. International Journal of Molecular Sciences 2018; 19(5): 1442 doi: 10.3390/ijms19051442
|
| 7 |
Iku Niinomi, Keiko Hosohata, Yasuhiro Mori, Yuki Yamaguchi, Tomohito Wakabayashi, Mayako Uchida, Kazunori Iwanaga. Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database. Journal of Pharmaceutical Health Care and Sciences 2019; 5(1) doi: 10.1186/s40780-019-0149-z
|
| 8 |
Raouf Hajji. Biosimilars in rheumatic diseases. International Journal of Clinical Practice 2021; 75(3) doi: 10.1111/ijcp.13709
|
| 9 |
Alessandro Armuzzi, Gionata Fiorino, Angela Variola, Natalia Manetti, Walter Fries, Ambrogio Orlando, Giovanni Maconi, Fabrizio Bossa, Maria Cappello, Livia Biancone, Laura Cantoro, Francesco Costa, Renata D’Incà, Paolo Lionetti, Mariabeatrice Principi, Fabiana Castiglione, Maria L Annunziata, Antonio Di Sabatino, Maria Di Girolamo, Maria M Terpin, Claudio C Cortelezzi, Simone Saibeni, Arnaldo Amato, Sandro Ardizzone, Luisa Guidi, Silvio Danese, Arianna Massella, Agostino Ventra, Giulia Rizzuto, Alessandro Massari, Francesco Perri, Vito Annese, Silvia Saettone, Roberto Tari, Carlo Petruzzellis, Gianmichele Meucci, Gianni Imperiali, Francesco W Guglielmi, Silvia Mazzuoli, Luigi Caserta, Maria Caterina Parodi, Agostino Colli, Anna Ronchetti, Daniela Pugliese, Andrea Geccherle, Francesca Rogai, Stefano Milani, Sara Renna, Andrea Cassinotti, Angelo Andriulli, Giuseppina Martino, Barbara Scrivo, Edoardo Troncone, Anna Kohn, Lorenzo Bertani, Greta Lorenzon, Silvia Ghione, Olga Nardone, Maurizio Vecchi, Angela Bertani, Matteo A Bosani, Cristina Bezzio, Raffaele Salerno. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases 2019; 25(3): 568 doi: 10.1093/ibd/izy264
|
| 10 |
Pieter Hindryckx, Gregor Novak. Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?. Best Practice & Research Clinical Gastroenterology 2018; : 9 doi: 10.1016/j.bpg.2018.05.004
|
| 11 |
Nadia Pillai, Judith E Lupatsch, Mark Dusheiko, Matthias Schwenkglenks, Michel Maillard, C Simone Sutherland, Valérie E H Pittet, Claudia Anderegg, Peter Bauerfeind, Christoph Beglinger, Stefan Begré, Dominique Belli, José M Bengoa, Luc Biedermann, Beat Bigler, Janek Binek, Mirjam Blattmann, Stephan Boehm, Jan Borovicka, Christian P Braegger, Nora Brunner, Patrick Bühr, Bernard Burnand, Emanuel Burri, Sophie Buyse, Matthias Cremer, Dominique H Criblez, Philippe de Saussure, Lukas Degen, Joakim Delarive, Christopher Doerig, Barbara Dora, Gian Dorta, Mara Egger, Tobias Ehmann, Ali El-Wafa, Matthias Engelmann, Jessica Ezri, Christian Felley, Markus Fliegner, Nicolas Fournier, Montserrat Fraga, Pascal Frei, Remus Frei, Michael Fried, Florian Froehlich, Christian Funk, Raoul Ivano Furlano, Suzanne Gallot-Lavallée, Martin Geyer, Marc Girardin, Delphine Golay, Tanja Grandinetti, Beat Gysi, Horst Haack, Johannes Haarer, Beat Helbling, Peter Hengstler, Denise Herzog, Cyrill Hess, Klaas Heyland, Thomas Hinterleitner, Philippe Hiroz, Claudia Hirschi, Petr Hruz, Rika Iwata, Res Jost, Pascal Juillerat, Céline Keller, Christina Knellwolf, Christoph Knoblauch, Henrik Köhler, Rebekka Koller, Claudia Krieger-Grübel, Gerd Kullak-Ublick, Patrizia Künzler, Markus Landolt, Rupprecht Lange, Frank Serge Lehmann, Andrew Macpherson, Philippe Maerten, Michel H Maillard, Christine Manser, Michael Manz, Urs Marbet, George Marx, Christoph Matter, Rémy Meier, Martina Mendanova, Pierre Michetti, Benjamin Misselwitz, Bernhard Morell, Patrick Mosler, Christian Mottet, Christoph Müller, Pascal Müller, Beat Müllhaupt, Claudia Münger-Beyeler, Leilla Musso, Andreas Nagy, Michaela Neagu, Cristina Nichita, Jan Niess, Andreas Nydegger, Nicole Obialo, Carl Oneta, Cassandra Oropesa, Ueli Peter, Daniel Peternac, Laetitia Marie Petit, Franziska Piccoli-Gfeller, Julia Beatrice Pilz, Valérie Pittet, Nadia Raschle, Ronald Rentsch, Sophie Restellini, Jean-Pierre Richterich, Sylvia Rihs, Marc Alain Ritz, Jocelyn Roduit, Daniela Rogler, Gerhard Rogler, Jean-Benoît Rossel, Vanessa Rueger, Gaby Saner, Bernhard Sauter, Mikael Sawatzki, Michela Schäppi, Michael Scharl, Sylvie Scharl, Martin Schelling, Susanne Schibli, Hugo Schlauri, Sybille Schmid Uebelhart, Jean-François Schnegg, Alain Schoepfer, Frank Seibold, Mariam Seirafi, Gian-Marco Semadeni, David Semela, Arne Senning, Marc Sidler, Christiane Sokollik, Johannes Spalinger, Holger Spangenberger, Philippe Stadler, Michael Steuerwald, Alex Straumann, Bigna Straumann-Funk, Michael Sulz, Alexandra Suter, Joël Thorens, Sarah Tiedemann, Radu Tutuian, Stephan Vavricka, Francesco Viani, Jürg Vögtlin, Roland Von Känel, Alain Vonlaufen, Dominique Vouillamoz, Rachel Vulliamy, Jürg Wermuth, Helene Werner, Paul Wiesel, Reiner Wiest, Tina Wylie, Jonas Zeitz, Dorothee Zimmermann. Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn’s Disease using Real-World Data. Journal of Crohn's and Colitis 2020; 14(4): 490 doi: 10.1093/ecco-jcc/jjz169
|
| 12 |
Eduardo Mysler, Valderilio Feijó Azevedo, Silvio Danese, Daniel Alvarez, Noriko Iikuni, Beverly Ingram, Markus Mueller, Laurent Peyrin-Biroulet. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. Drugs 2021; 81(16): 1859 doi: 10.1007/s40265-021-01610-1
|
| 13 |
Andras Tarnok, Zoltan Kiss, Orsolya Kadenczki, Gabor Veres. Characteristics of biological therapy in pediatric patients with Crohn’s disease. Expert Opinion on Biological Therapy 2019; 19(3): 181 doi: 10.1080/14712598.2019.1564034
|
| 14 |
Hong Wu, Qingxia You, Yi Jiang, Fangxiang Mu. Tumor necrosis factor inhibitors as therapeutic agents for recurrent spontaneous abortion (Review). Molecular Medicine Reports 2021; 24(6) doi: 10.3892/mmr.2021.12487
|
| 15 |
Dongmun Ha, Seung Eun Lee, Inmyung Song, Sung Jun Lim, Ju-Young Shin. Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005–2016. Clinical Rheumatology 2020; 39(2): 347 doi: 10.1007/s10067-019-04802-z
|
| 16 |
Bojan Čalija, Jela Milić. Targeted delivery of anti-inflammatory drugs in lower parts of gastrointestinal tract: Conventional and novel approaches. Arhiv za farmaciju 2017; 67(3): 124 doi: 10.5937/arhfarm1702124C
|
| 17 |
Daniel J Wong, Eve M Roth, Joseph D Feuerstein, Vitaliy Y Poylin. Surgery in the age of biologics. Gastroenterology Report 2019; 7(2): 77 doi: 10.1093/gastro/goz004
|
| 18 |
Aniket Mali, Apurva Sawant, Anagha Mahadik, Sujit Nair. Immunotherapy – A Novel Facet of Modern Therapeutics. 2021; : 63 doi: 10.1007/978-981-15-9038-2_4
|
| 19 |
Sam Reed. The Emerging Treatment Landscape of Inflammatory Bowel Disease: Role of Innovator Biologics and Biosimilars. EMJ Gastroenterology 2018; : 50 doi: 10.33590/emjgastroenterol/10314260
|
| 20 |
Dana Rachel Berg, Jean-Frederic Colombel, Ryan Ungaro. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019; 25(12): 1896 doi: 10.1093/ibd/izz059
|
| 21 |
Yijie Song, Man Yuan, Yu Xu, Hongxi Xu. Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing. Pharmaceuticals 2022; 15(9): 1080 doi: 10.3390/ph15091080
|
| 22 |
HoUng Kim, Rieke Alten, Luisa Avedano, Axel Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M. Irving, Jørgen Jahnsen, Péter L. Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven Simoens, Rene Westhovens, Silvio Danese, Ji Hoon Jeong. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020; 80(2): 99 doi: 10.1007/s40265-020-01256-5
|
| 23 |
Andrew Motlis, Moheb Boktor, Paul Jordan, Urska Cvek, Marjan Trutschl, J. Steven Alexander. Two year follow-up of Crohn’s patients substituted to certolizumab anti-TNFa therapy: SAVANT 2. Pathophysiology 2017; 24(4): 291 doi: 10.1016/j.pathophys.2017.07.004
|
| 24 |
Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei, Shashi Adsul. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. Gut and Liver 2020; 14(6): 685 doi: 10.5009/gnl19209
|
| 25 |
Vito Annese. Biosimilars in IBD: Similarity Breeds Contented Patients. Digestive Diseases and Sciences 2019; 64(6): 1399 doi: 10.1007/s10620-019-05499-5
|